# A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Study · id `cardio:ct-nct03152552` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03152552](<https://clinicaltrials.gov/study/NCT03152552>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03152552

Browse, organ or system: Heart; Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Heart failure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 125 participants.

## Technical summary

Registry record NCT03152552. Randomized; triple masking; primary purpose treatment. Start 2017-07-25 (actual); primary completion 2018-06-06 (actual). Results posted on 2019-08-28.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Started: 2017-07-25 (actual) (ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Primary completion: 2018-06-06 (actual) (ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Completion: 2018-06-06 (actual) (ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Results first posted: 2019-08-28 (ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Belgium; Bulgaria; Canada; Croatia; Czechia; Denmark; Germany; Hungary; Ireland; Italy; Mexico; Netherlands; Norway; Poland; Puerto Rico; Singapore; South Africa; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03152552, source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03152552-2019-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
- Condition: Diabetes Mellitus and Heart Failure
- Intervention (Drug): LIK066
- Intervention (Drug): Placebo
- Intervention (Drug): Empagliflozin
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8c6c99a674a0a5c49bea50ea9f70dc8a52be14a0a86ef5fad210433a5d3f7921
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
